Discover
ALLK
Allakos Inc.
0.33
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | -72.80% | |
| 1y | -72.34% |
0.33
day range
0.33
52 week range
| Open | 0.33 | Prev Close | 0.33 | Low | 0.33 | High | 0.33 | Mkt Cap | N/A |
| Vol | 724.80K | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -2.02 |
| Beta | 1.02 | Short Ratio | 1.78 | Inst. Own | 81.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 3.35 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.22 | -0.21 | 0.01 | 4.55% |
| 2024-08-07 | 2024-06 | -0.32 | -0.3 | 0.02 | 6.25% |
| 2024-08-07 | 2024-06 | -0.32 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.41 | -0.5 | -0.09 | -21.95% |
| 2024-05-09 | 2024-03 | -0.41 | N/A | N/A | N/A |
| 2024-03-14 | 2023-12 | -0.53 | -0.71 | -0.18 | -33.96% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-09-26 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-07-18 | Jefferies | Upgrade | Hold | Hold |
| 2024-06-26 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-06-20 | Cantor Fitzgerald | Upgrade | Neutral | |
| 2024-01-17 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-01-17 | Barclays | Upgrade | Underweight | Underweight |
Profile
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-01-05 | ALEXANDER ROBERT ALLEN | Chief Executive Officer | 1.38M | Stock Award(Grant) |
| 2023-01-05 | PATERSON CRAIG A. | Officer | 372.47K | Stock Award(Grant) |
| 2024-06-27 | RADFORD HARLAN BAIRD III | Chief Financial Officer | 204.39K | Sale |
| 2023-01-05 | TOMASI ADAM | President | 748.69K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BVF Inc. | 16.55M | 21.02M | 18.53% |
| 2024-09-29 | NEA Management Company, LLC | 6.15M | 7.81M | 6.88% |
| 2024-09-29 | FMR, LLC | 5.37M | 6.82M | 6.01% |
| 2024-09-29 | Deep Track Capital, Lp | 5.00M | 6.35M | 5.60% |
| 2024-09-29 | Vanguard Group Inc | 3.51M | 4.46M | 3.93% |
| 2024-09-29 | Redmile Group, LLC | 3.08M | 3.91M | 3.44% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 4.86M | 6.17M | 5.44% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.34M | 2.97M | 2.62% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.01M | 1.28M | 1.13% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 433.25K | 550.23K | 0.48% |
| 2024-10-30 | Fidelity Enhanced Small Cap ETF | 338.20K | 429.51K | 0.38% |
| 2024-10-30 | iShares Micro Cap ETF | 180.63K | 229.40K | 0.20% |